Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Xie E, Yeo YH, Scheiner B, Zhang Y, Hiraoka A, Tantai X, Fessas P, de Castro T, D'Alessio A, Fulgenzi CAM, Xu S, Tsai HM, Kambhampati S, Wang W, Keenan BP, Gao X, Xing Z, Pinter M, Lin YJ, Guo Z, Vogel A, Tanaka T, Kuo HY, Kelley RK, Kudo M, Yang JD, Pinato DJ, Ji F. Xie E, et al. Among authors: kambhampati s. JAMA Oncol. 2023 Oct 1;9(10):1423-1431. doi: 10.1001/jamaoncol.2023.3284. JAMA Oncol. 2023. PMID: 37615958 Free PMC article.
Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma.
Ladbury C, Dandapani S, Hao C, Fabros M, Amini A, Sampath S, Glaser S, Sokolov K, Yeh J, Baird JH, Kambhampati S, Herrera A, Mei M, Nikolaenko L, Shouse G, Budde LE. Ladbury C, et al. Among authors: kambhampati s. Cancers (Basel). 2023 Mar 14;15(6):1747. doi: 10.3390/cancers15061747. Cancers (Basel). 2023. PMID: 36980632 Free PMC article.
Management of aggressive lymphoma after CAR T-cell therapy failure.
Nastoupil LJ, Kambhampati S. Nastoupil LJ, et al. Among authors: kambhampati s. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):364-369. doi: 10.1182/hematology.2023000437. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066908 Review.
Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Torka P, Kambhampati S, Chen L, Wang X, Chen C, Vuong D, Qin H, Muir A, Orand K, Borja I, Lynne Smith D, Herrera AF, Spurgeon SEF, Park B, Lewis LD, Hernandez-Ilizaliturri F, Xia Z, Danilov AV. Torka P, et al. Among authors: kambhampati s. Blood Cancer J. 2023 Jan 11;13(1):9. doi: 10.1038/s41408-022-00763-w. Blood Cancer J. 2023. PMID: 36631449 Free PMC article.
Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia.
Wang X, Chen C, Vuong D, Rodriguez-Rodriguez S, Lam V, Roleder C, Wang JH, Kambhampati S, Berger A, Pennock N, Torka P, Hernandez-Ilizaliturri F, Siddiqi T, Wang L, Xia Z, Danilov AV. Wang X, et al. Among authors: kambhampati s. Leukemia. 2023 Jun;37(6):1324-1335. doi: 10.1038/s41375-023-01889-x. Epub 2023 Apr 8. Leukemia. 2023. PMID: 37031300 Free PMC article.
282 results